Cargando…
Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment
OBJECTIVE: The maturation of oocytes to acquire competence for fertilization is critical to the success of in vitro fertilization (IVF) treatment. It requires LH-like exposure, provided by either human chorionic gonadotropin (hCG), or gonadotropin releasing hormone agonist (GnRHa). More recently, th...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573298/ https://www.ncbi.nlm.nih.gov/pubmed/33123084 http://dx.doi.org/10.3389/fendo.2020.537205 |
_version_ | 1783597411153739776 |
---|---|
author | Abbara, Ali Hunjan, Tia Ho, Vu N. A. Clarke, Sophie A. Comninos, Alexander N. Izzi-Engbeaya, Chioma Ho, Tuong M. Trew, Geoffrey H. Hramyka, Artsiom Kelsey, Tom Salim, Rehan Humaidan, Peter Vuong, Lan N. Dhillo, Waljit S. |
author_facet | Abbara, Ali Hunjan, Tia Ho, Vu N. A. Clarke, Sophie A. Comninos, Alexander N. Izzi-Engbeaya, Chioma Ho, Tuong M. Trew, Geoffrey H. Hramyka, Artsiom Kelsey, Tom Salim, Rehan Humaidan, Peter Vuong, Lan N. Dhillo, Waljit S. |
author_sort | Abbara, Ali |
collection | PubMed |
description | OBJECTIVE: The maturation of oocytes to acquire competence for fertilization is critical to the success of in vitro fertilization (IVF) treatment. It requires LH-like exposure, provided by either human chorionic gonadotropin (hCG), or gonadotropin releasing hormone agonist (GnRHa). More recently, the hypothalamic stimulator, kisspeptin, was used to mature oocytes. Herein, we examine the relationship between the endocrine changes following these agents and oocyte maturation. DESIGN: Retrospective cohort study. METHODS: Prospectively collected hormonal data from 499 research IVF cycles triggered with either hCG, GnRHa, or kisspeptin were evaluated. RESULTS: HCG-levels (121 iU/L) peaked at 24 h following hCG, whereas LH-levels peaked at ~4 h following GnRHa (140 iU/L), or kisspeptin (41 iU/L). HCG-levels were negatively associated with body-weight, whereas LH rises following GnRHa and kisspeptin were positively predicted by pre-trigger LH values. The odds of achieving the median mature oocyte yield for each trigger were increased by hCG/LH level. Progesterone rise during oocyte maturation occurred precipitously following each trigger and strongly predicted the number of mature oocytes retrieved. Progesterone rise was positively associated with the hCG-level following hCG trigger, but negatively with LH rise following all three triggers. The rise in progesterone per mature oocyte at 12 h was greater following GnRHa than following hCG or kisspeptin triggers. CONCLUSION: The endocrine response during oocyte maturation significantly differed by each trigger. Counter-intuitively, progesterone rise during oocyte maturation was negatively associated with LH rise, even when accounting for the number of mature oocytes retrieved. These data expand our understanding of the endocrine changes during oocyte maturation and inform the design of future precision-triggering protocols. |
format | Online Article Text |
id | pubmed-7573298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75732982020-10-28 Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment Abbara, Ali Hunjan, Tia Ho, Vu N. A. Clarke, Sophie A. Comninos, Alexander N. Izzi-Engbeaya, Chioma Ho, Tuong M. Trew, Geoffrey H. Hramyka, Artsiom Kelsey, Tom Salim, Rehan Humaidan, Peter Vuong, Lan N. Dhillo, Waljit S. Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: The maturation of oocytes to acquire competence for fertilization is critical to the success of in vitro fertilization (IVF) treatment. It requires LH-like exposure, provided by either human chorionic gonadotropin (hCG), or gonadotropin releasing hormone agonist (GnRHa). More recently, the hypothalamic stimulator, kisspeptin, was used to mature oocytes. Herein, we examine the relationship between the endocrine changes following these agents and oocyte maturation. DESIGN: Retrospective cohort study. METHODS: Prospectively collected hormonal data from 499 research IVF cycles triggered with either hCG, GnRHa, or kisspeptin were evaluated. RESULTS: HCG-levels (121 iU/L) peaked at 24 h following hCG, whereas LH-levels peaked at ~4 h following GnRHa (140 iU/L), or kisspeptin (41 iU/L). HCG-levels were negatively associated with body-weight, whereas LH rises following GnRHa and kisspeptin were positively predicted by pre-trigger LH values. The odds of achieving the median mature oocyte yield for each trigger were increased by hCG/LH level. Progesterone rise during oocyte maturation occurred precipitously following each trigger and strongly predicted the number of mature oocytes retrieved. Progesterone rise was positively associated with the hCG-level following hCG trigger, but negatively with LH rise following all three triggers. The rise in progesterone per mature oocyte at 12 h was greater following GnRHa than following hCG or kisspeptin triggers. CONCLUSION: The endocrine response during oocyte maturation significantly differed by each trigger. Counter-intuitively, progesterone rise during oocyte maturation was negatively associated with LH rise, even when accounting for the number of mature oocytes retrieved. These data expand our understanding of the endocrine changes during oocyte maturation and inform the design of future precision-triggering protocols. Frontiers Media S.A. 2020-10-06 /pmc/articles/PMC7573298/ /pubmed/33123084 http://dx.doi.org/10.3389/fendo.2020.537205 Text en Copyright © 2020 Abbara, Hunjan, Ho, Clarke, Comninos, Izzi-Engbeaya, Ho, Trew, Hramyka, Kelsey, Salim, Humaidan, Vuong and Dhillo http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Abbara, Ali Hunjan, Tia Ho, Vu N. A. Clarke, Sophie A. Comninos, Alexander N. Izzi-Engbeaya, Chioma Ho, Tuong M. Trew, Geoffrey H. Hramyka, Artsiom Kelsey, Tom Salim, Rehan Humaidan, Peter Vuong, Lan N. Dhillo, Waljit S. Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment |
title | Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment |
title_full | Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment |
title_fullStr | Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment |
title_full_unstemmed | Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment |
title_short | Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment |
title_sort | endocrine requirements for oocyte maturation following hcg, gnrh agonist, and kisspeptin during ivf treatment |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573298/ https://www.ncbi.nlm.nih.gov/pubmed/33123084 http://dx.doi.org/10.3389/fendo.2020.537205 |
work_keys_str_mv | AT abbaraali endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT hunjantia endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT hovuna endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT clarkesophiea endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT comninosalexandern endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT izziengbeayachioma endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT hotuongm endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT trewgeoffreyh endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT hramykaartsiom endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT kelseytom endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT salimrehan endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT humaidanpeter endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT vuonglann endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment AT dhillowaljits endocrinerequirementsforoocytematurationfollowinghcggnrhagonistandkisspeptinduringivftreatment |